NCT04029909 - A Clinical Study of Gimatecan in Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 11, 2019

Primary Completion Date

December 31, 2019

Study Completion Date

December 31, 2022

Conditions

Ovarian Epithelial CancerFallopian Tube CancerPrimary Peritoneal Cancer

Interventions

DRUG

Gimatecan 0.6mg/m2/d

0.6mg/m2/d for once a day for 5 consecutive days of Gimatecan

DRUG

0.8mg/m2/d

0.8mg/m2/d for once a day for 5 consecutive days of Gimatecan

DRUG

0.4mg/m2/d

0.4mg/m2/d for once a day for 5 consecutive days of Gimatecan

Trial Locations (1)

RECRUITING

Beijing Tumor Hospital, Beijing